

Figure S1





Figure S2 A

```

Human_PELP1      1  MAAAVLSGSPSAGSAAGVPGGTGGLSAVSSGPRRLRLLLLESVSG-----LLOPRTGSAVAPVHPPNRSAPHLPGLMCLLR--LHGSVGGAQN
Yeast_Rix1      1  -----MSEEFAVSTLARN-----LEIAKGNEFHTILATLRS-----PVYIN-----EQLLKSELSFLVTKILK

Human_PELP1     88  LGALVSTSNARLSSIKTRFEGLCLLS-----LLVGESPTELFQOHCVSWLRSIQQVLOTQDPPATMELAVAVLRDLLR-----YAAQLPAL
Yeast_Rix1     58  SGNDFDLWKGCHTSVVTCAYNPLVLSTHGGOLLAIYSRLEQKTGFYSSVISSSHGKOLFN---TLISSVAIIDLMKNKPTLSREALVPKL

Human_PELP1    172  ISMNHLPGLLTSILGLRECEQSALEG-MKACMTYFPRACGSLKGKLASFFLSRVDATSPOLOLACECYSRLPSLGAGFSQG-----
Yeast_Rix1    150  I-----PTLIT-LSQYEPELVLPVLQRILKRNTTTFKPFTNKFRTVLINLIISDYASIGTKTORLVCENFAYLHLLKIQVSDTSDDETQAHH

Human_PELP1    256  HTESWEQELHSLTASLH---TLG-----ALYEGAETAPVQNEGPGVEMLSSEDGDAHVLLOLR---QRFSGLARCLGLMLSSEFGA
Yeast_Rix1    239  ADSNWRTGLMSILSQFKPIQLCEILDFEQDNELYKLIKSLPVIDESNNKEEFLPSLKLDFNAPLTLWEIPORLSLLADMLVAFISLPTPF

Human_PELP1    336  VPVQEILDFICRTISVSK---NISLHGDGPLR---LLLLPSIHLEALDILSALILACGSRLLRF--GILIGRLLPQVLNSWSIG-RDSLS
Yeast_Rix1    334  VPLGGINSLCEVLLGVSNKYLPLKKELRHDNELNGVINTILPOLQFOGIRLWEIMVSKYCRCGLSFEGILSSIELFIPLKKKSNNEIDFNV

Human_PELP1    420  QERPYSTVRTKVYAILELVQVCGASAGMLQGGASEALLTHLLSDISPP---ADALKLRSPRGSPD-----GSLOTGKPSAPKKLL
Yeast_Rix1    429  LKFEFAVFRLVNMILS-----HLGHOLNISVISOLIEVALFLSHDKTLIDSLFKNRKSIMKQOTKTKOSKRSKS

Human_PELP1    503  EAMAPPSHRKGDSNANS-----DVCAALRGLSRTILMCGPLIKEETHRRLHDIVIPLVMGVQQEVLGSSPYTSSRCRRELYCLLAL
Yeast_Rix1    503  AFSDIYTHPELFVCKNSMNWFNEINDFFITALN---NWILPSTPHIQILKYSITOSIRL-----KERFGYIPES-----FVNLLRCE

Human_PELP1    590  P-SPRCPPLACALQAFSLGORE--DSLEVSSFCSEALVTCAALTHPRVPPLQPMGPTCPTAPVPPPEAPSPFRAPPFHPPGMPSVGSMP
Yeast_Rix1    580  PGSERVS---ILPIAISLLKNINDDMFEL-----LCHPKVP-----VG-----

Human_PELP1    682  PMPSAGPMFSAGVPSARPGPTTANHLGLSVPGLVSVPPRLLPGPENHRAGSNEDPILAPSGTPPTIPPDETFGGRVPRPAFVHDKEA
Yeast_Rix1    615  -MVYQLHKP-----LDLGEDGEVR-----DDINK-----KE-----

Human_PELP1    777  EISLESDSDDSVVIVPEGLPLPPPPPSGATPPIAPTGPPTASPPVAKEEPELPAAPGLPPPPPPPPVPGVTLPPP-QLVPEGTPG
Yeast_Rix1    641  ET-NESSN-----ANTGLETLK---ALENLEN-----VTIPEPKHEVPK-----

Human_PELP1    871  PPALEEDLTVININSDEEEEEE-----EEEEEEEEEEEEDFEEEEEDEEYFEEEEEEEFEEEEEEEEEEEEEEEEEEEEEEEEEEEEEEEEEEEE
Yeast_Rix1    677  ---VVDDTAIFKKRSVEEVIERESTSSHKKVKFVEETTVDNGEELIVKKAVSQTKEEEKPMEDSEDEE---QEFEFEIPAIELSD-----DEE

Human_PELP1    956  ELEEVEDLFGTAGGEVEEGAPPPPTLPPALPPPESPPKVQEPEPEPGLLLEVEEPGTEERGADTAPTLAPEALPSQGEVEREGESPAAG
Yeast_Rix1    761  EGE-----

Human_PELP1    1051 QELVEEEPSAPPTLLEEETEDGSDKVQPPPETAEEEMETETEAEALQEKEQDDTAAMLADFIDCPPDEKPPPPTEPDS
Yeast_Rix1    -----

```

Figure S2 B

```

Human_TEX10 1 MTKKRKRQ--HDFQKVKLKVGGKPKLONATPTNFKTKTIHLPEQLKEDGTLPTNNKLNKDLSSOMHHYNAGVKQSALLGLKDLLSOYP
Yeast_IPI1 1 MTKSRKQKQKKQDFLRKKLKVGGPKKRNATDTSFVSKTISRNOHLDQNPDLTKR-----LTLKHHNINVRKETLTTFFQKSIPS--

Human_TEX10 93 DAHLSNITSEVTAVFTDKDANVRLAAVQLLOFLAPKIRAEQISPFPLVSAHLSSAMTHTEGIEEDSLKVLIDILLEQYPALITGRSSILTK
Yeast_IPI1 87 SRLMTPLLTQSIPLICDESQQVROGLIDLVDIEIG-SHDAEILKLHCNIFVLYINMAMTHIVTQIQADSTKFLSHLLKYCGDEVVRKSWVKLL

Human_TEX10 188 ELISHQQLSKGLINRDRSQSWILSVNPNRRLTSQQWRLKVLVRLSKFLQALADGSSRLRESEGLQEOKENPHATSNSIFINWKEHANDQOHI
Yeast_IPI1 181 FGVLG-----WGOVGNDSAS

Human_TEX10 283 ENGGSQPNVSSQFRLRYLVGGLSGVDEGLSSTENLKGFIIEIIPLLIECWVEAVPPQLATPVGNGIEREPLQVMQOVLNIIISLLWKLSKQQD
Yeast_IPI1 200 TKKRNAKYVTIHLNALVTLVEYGCQDERARSDG-----DTA

Human_TEX10 378 KLESWLRKNYLLIDFKHHFMSRFPYVLKEITKHKRKEPNKSIKHCTVLSNNDHLLNLTSDIMVSLANASTLQKDCSWIEMIRKFFVTETLE
Yeast_IPI1 239 EDSGTLRNPVLIIPDYQPFELKLFTRKLVQDATSSG-----VNAVLSLATQDIDTRKAVFIEQFLPIVRKKIEVIK

Human_TEX10 473 RLNSKQLNRLLGVSWRMLQIQPNREDTETLIKAVYTLYQORGLILPVRTLLKFFSKYIYQTEELRSCFRYRSKVLSRWLAGLPLQLAHLGS
Yeast_IPI1 317 ECGKSAN-----KLKTLAKIFD-----

Human_TEX10 568 ELSTQLIDIHTAAARANKELLKSLQATALRIYDPOEGAVVVLPAQSQRRLVQLVYFLPSLPADLLSRLSRCCIMGRSSSLAAMLIGILHM
Yeast_IPI1 -----

Human_TEX10 663 FSGWKYSAKDWLMSDVDYFSFLFSTLTGFSKEELTWLQSLRGVPHVIQTQLSPVLLYLTDLQFLHHDVTEAVFHSLLVIPARSONFDILQ
Yeast_IPI1 -----

Human_TEX10 758 SKHLVGLTVIPDSTAGCVFGVICKLLDHTCVVSETLLPFLASCCYSLLYFLLTIEKGEAEHLRKRDKLWGVCSILALLPRVLRMLQSLRV
Yeast_IPI1 -----

Human_TEX10 853 GPEELPVVGQLRLLQLHAPLRTHMLTNAILVQOIKNITTLKSGSVQEQWLTDLHYCFNVYITGHPQGPSALATVY
Yeast_IPI1 -----

```

Figure S2 C

```

Human_WDR18   1  MAAPMEVAVCTDSAAPMWSCIVWELHSGANLTYRGGQAGPRGLALLNGEYLLAAQLGKNYTSAWELQ---RKDQLQOKIMCPGPVTCITAS
Yeast_IPI3    1  --MDEQVIFTTNTSGTIASVHSFEQIN----LRQCSTQSRNSCVQVGN-KYLFIAQAQKALINVYNLSGSFKRESVEQRLPLPEILKCLEVV

Human_WDR18   93  -----LYVVLAVGVAESIHL--WEVSTGNLL-VILSRHYQDVSCLOFTGDSSHFTSGGKDCLVLVWS---LCSVLOADPS
Yeast_IPI3    89  GVQYDRIQGVNHNLPDFNLPYLLLGSTESGKLYIWEIWSGILLNVKPMAYOSITKIKSILNGKYIITSGNDSRVIWQTVDLVSASNDP-

Human_WDR18   163 APRHVWSHALPIIDLHCG--FGGPIARVAT-----SSLDQTVKLWEVSSGE---LLLSVLFVDSIMAVTMDLAEHH
Yeast_IPI3    180 KPLCILHDHTLPVTDFOVSSSQGKFLSCTDTKLFTVSQDATIRCYDLSLIGSKKKQKANENDVSIKTPVLLATFTTPYSIKSIVLDPADRA

Human_WDR18   233 GSGESIFQVDLFTWPGQRESRFHPEQDAGK--VFKG-----HRN-----QVTCISVSTDGSVLLSGSH
Yeast_IPI3    275 GTAEG-CFSLNLFYKLG-NAIVNLLQSAGVNTVQGRVFSLVQRNLSLTGGENEDLDALYAMGQVCENVLNSNVSCLEISMDGTLILLIGDT

Human_WDR18   293 VRLWDVQSKQCIRTVALK-----GPVTNAAILLAPVSM-----SSDFRPS-----LPLPHFNKHLGAEHGDEPRHG
Yeast_IPI3    368 VSIAEIVSKQIIRTIQTLTTSQDSVGEVTN---LLTNPYRLEKRNLLFEGESKGGKOPSNNNGHNFMKIPNLQRVIFDGKNGHLHDIWYQIG


Human_WDR18   357 -----LTLRLG----LHQ---QGSEPS-----YLDRTQQLQAVLCSTMEKSVLGG-QDQIRVRVTLEDEVRNLRKINRDL
Yeast_IPI3    460 AETDPNLALPLNDFNAYLEQVKTOESIFSHIGKVSSNVKVIDNKIDATSSLDSNAAKDEEITELKTNIEALTHAYKELRDMHEKLYEHOOM

Human_WDR18   423 STRFITRPAK
Yeast_IPI3    555 Q-----

```


Figure S3

A



B





Figure S4


A




Unique peptides of MDN1 identified by MS/MS :

155 FLQQEQSVFR 164
 222 LLEEAQLQDLEK 233
 2489 IMQSPSPENLK 2499
 3269 NLSSQLQTGR 3278
 3340 APAVQDLLTR 3349
 3361 SAQVAQSLLK 3370
 4206 LNAALATPAK 4215
 5509 VLAAVQAAR 5517
 5547 GPGEMPEIR 555

B



C



D




Figure S5





Figure S6

A



B




Figure S7




Figure S8




Figure S9






Figure S10

A



B



C








Figure S11


A

siSENP3



B

siControl



siSENP3




Figure S12






Figure S13

A



B

siPELP1



siPELP1 + siSENP3






Figure S14




Figure S15




Figure S16





Figure S17



Legends to Supplementary Figures

Fig S1: PELP1, TEX10 and WDR18 co-purify with Flag-SENP3.

(A) Flag-tagged SENP3 was expressed in HEK293T cells and purified on a Flag-affinity column. Bound proteins were eluted with Flag-peptide, separated by SDS-PAGE and analyzed by mass-spectrometry. PELP1, LAS1L, TEX10, WDR18 and NPM1 were identified by MASCOT algorithms in individual bands as indicated. Vertical lines indicate removal of irrelevant neighbouring lanes from the initial gel. The corresponding original scan is provided in Supplementary Figure 15. (B) Diagram showing conserved domains of PELP1, TEX10 and WDR18 and their corresponding yeast counterparts. The PELP1 family of higher eukaryotes harbours a NUC201/202 domain (Pfam accession: PF08167), which is found in hypothetical nucleolar proteins. GLU represents the glutamic acid rich C-terminal region of PELP1 and Rix1. Tex10 and Ipi1 share the Ipi1N domain (Pfam accession: PF12333), which defines the eukaryotic Tex10/Ipi1 family. In TEX10 a heat repeat (Pfam accession: PF00514) can be found. WDR18 and IPI3 have WD40 repeats (Pfam accession: PF00400) in common.

Fig S2: Sequence comparison of PELP1-TEX10-WDR18 with Rix1-Ipi1-Ipi3.

(A) Human PELP1 (accession Q8IZL8) was aligned to *S. cerevisiae* Rix-1 (accession P38883). (B) Human TEX10 (accession Q9NXF1) was aligned to *S. cerevisiae* IPI1 (accession P38803). (C) Human WDR18 (accession Q9BV38) was aligned to *S. cerevisiae* IPI3 (accession P53877).

Fig S3: Interdependency of PELP1 and WDR18.

(A) Endogenous PELP1 was immunoprecipitated from HeLa cells with a rabbit polyclonal antibody from control extracts or extracts treated with RNase A respectively. Immunocomplexes were probed for the presence of endogenous WDR18 by western blotting with an anti-WDR18 antibody. Right panel: Efficient digestion of RNA by RNase A treatment was verified by RT-PCR using primers for the indicated rRNA region. (B) HeLa cells were transfected with the indicated siRNAs and protein levels were monitored by western blotting as indicated. Detection of β -tubulin served as loading control.

Fig S4: MDN1 and LAS1L are associated with PELP1.

(A) Flag-tagged PELP1 was expressed in HeLa cells and purified on a Flag-affinity column. Bound proteins were separated by SDS-PAGE and the higher molecular weight region above 250 kDa was cut out of the gel and analyzed by mass-spectrometry. MS/MS identified nine unique peptides corresponding to human MDN1 as indicated. In the respective control sample only one

peptide of MDN1 was identified. Vertical lines indicate removal of irrelevant neighbouring lanes from the initial gel. The corresponding original scan is provided in Supplementary Figure 16. (B) Flag-PELP1 was expressed in HeLa cells, captured on Flag-beads, and the presence of endogenous MDN1 was tested by immunoblotting as indicated. (C, D) Endogenous PELP1 was immunoprecipitated from HeLa cells with a rabbit polyclonal antibody and probed using western blotting with the indicated antibodies. The inputs represent 2.5 % of the total cell lysate.

Fig S5: A subfraction of PELP1, TEX10 and WDR18 localizes to the nucleolus.

HeLa cells were fractionated into cytoplasmic (Cp), nuclear (N), nucleoplasmic (Np) and nucleolar (No) fractions and the respective fractions were investigated for the presence of PELP1, TEX10 and WDR18 by western blotting as indicated. The following proteins served as markers for the respective fractions. Cp: beta-tubulin, Np: U2AF65 (a splicing factor), No: anti-Fibrillarin. WCE: whole cell extract. Vertical lines indicate removal (upper four panels) or swapping (lower two panels) of neighbouring lanes. The original scan is provided in Supplementary Figure 17.

Fig S6: PELP1 coimmunoprecipitates with NPM1.

(A) Flag-tagged NPM1 was expressed in U2OS cells, captured on Flag-beads and immunoblotted for the presence of endogenous PELP1 as indicated. (B) Endogenous NPM1 was immunoprecipitated from OCI-AML3 cells using a mouse monoclonal antibody (Invitrogen) and immunocomplexes were probed for the presence of endogenous PELP1. The inputs represent 2.5 % of the total cell lysate.

Fig S7: LAS1L, MDN1 and TEX10 can be found in the nucleolus.

Localization of LAS1L, MDN1 or TEX10 was examined by indirect fluorescence using anti-LAS1L, anti-MDN1 or anti-TEX10 antibodies as indicated. Nuclei were counterstained with DAPI.

Fig S8: siRNA-mediated downregulation of TEX10 and MDN1.

Real time quantitative PCR was performed to verify the decreased mRNA levels of TEX10 and MDN1 following siRNA treatment. Relative expression levels are calculated by dividing the corresponding values for TEX10 and MDN1 by values for the indicated control genes (HPRT= Hypoxanthine-guanine phosphoribosyltransferase/ PBGD=porphobilinogen deaminase). Relative expression levels in control siRNA treated cells were set at 1.

Fig S9: Profile of UV absorbance obtained upon fractionation of nuclear extracts on a sucrose gradient.

After ultracentrifugation of the gradients 20 fractions were collected and A_{254} was recorded. As a result two major peaks appeared containing small and large ribosomal subunits, respectively, and their precursors.

Fig S10: PELP1 binds to SUMO in a covalent and non-covalent fashion.

(A) GST-tagged versions of SUMO1 and SUMO2 as well as GST alone were purified in *E. coli* and incubated with ^{35}S -labeled in vitro translated versions of full length PELP1 and PELP1 mutants as indicated. (B) PELP1 was generated by in vitro transcription/translation and incubated with recombinant E1 and E2 enzymes and SUMO1 or SUMO2 respectively in the presence of ATP. In the control reaction (lane 1) SUMO was omitted. Where indicated wild-type SENP3 or the catalytically inactive SENP3^{C532S} version - generated by in vitro transcription/translation - was added to the reactions. (C) PELP1^{WT} and PELP1^{K826R} were generated by in vitro transcription/translation and sumoylated in the presence of recombinant E1, E2, SUMO1 or SUMO2, respectively, and ATP. In the control lanes (lane 1 and 4) SUMO was not added.

Fig S11: SENP3 depletion leads to delocalization of MDN1, but not of WDR50/Utp18.

(A, B) HeLa cells were transfected with SENP3 siRNA. After fixation and permeabilization the localization of PELP1, WDR50 or MDN1 respectively was monitored by indirect fluorescence using anti-PELP1, anti-WDR50 or anti-MDN1 antibodies as indicated. Nuclei were counterstained with DAPI.

Fig S12: Depletion of PES1 does not affect binding of PELP1 to WDR18.

Endogenous PELP1 was immunoprecipitated from cells treated with a control siRNA and cells treated with an siRNA directed against PES1, respectively. The presence of endogenous WDR18 was tested by western blotting. Inputs represent 2.5 % of the total cell lysate.

Fig S13: Localization of Flag-PELP1^{IV790/1AA,VI880/1AA}-SUMO2, HA-PELP1^{K826R} and HA-PELP1^{IV790/1AA,VI880/1AA}.

(A, B) HeLa cells were transfected with the indicated siRNAs and PELP1 versions. After fixation and permeabilization their localization was analyzed using anti-Flag or anti-HA antibodies, respectively. Nuclei were counterstained with DAPI.

Fig S14: Original scan of Figure 7C.

Lanes 1, 2 and 3 of both input and pull down were taken to assemble Figure 7C. The other lanes were removed as they were not relevant for the actual figure.

Fig S15: Original scan of Figure S1A.

Lanes 1, 2 and 3 were composed to arrange Figure S1A. The remaining lanes were not included as they were irrelevant in this context.

Fig S16: Original scan of Figure S4A.

Lanes 1, 2 and 3 were merged to form Figure S4A. The other lanes were not included as they were negligible for the actual figure.

Fig S17: Original scans of Figure S5.

Lanes 6 in the original scans were depleted as they were not relevant for Figure S5. In addition, for anti-U2AF65 as well as for anti-Fibrillarin (right panel), lanes 4 and 5 of the original scan were swapped in order to be in line with the order of the other immunoblots of the actual figure.